Trans Ova Genetics

Trans Ova Genetics provides industry-leading reproductive technologies and expertise to cattle breeders through a unique professional services team that works closely with clients to understand their breeding goals, and ultimately help clients advance and extend superior genetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

news image

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

news image

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More

DIAGNOSTICS

RQ BIO LAUNCHES WITH GOAL TO TRANSFORM TREATMENT AND PREVENTION OF VIRAL INFECTIOUS DISEASES THROUGH ANTIBODY TECHNOLOGIES

RQ Bio | May 17, 2022

news image

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging a...

Read More

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

news image

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More
news image

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More
news image

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More
news image

DIAGNOSTICS

RQ BIO LAUNCHES WITH GOAL TO TRANSFORM TREATMENT AND PREVENTION OF VIRAL INFECTIOUS DISEASES THROUGH ANTIBODY TECHNOLOGIES

RQ Bio | May 17, 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging a...

Read More
news image

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More